GLP1R and diabetes mellitus: Subsequent trials enrolled patients with stage II–III CKD and micro-macroalbuminuria with or without diabetes, and demonstrated that SGLT2i reduced the risk of ESKD, heart failure, and cardiovascular events.5, 6, 7 Such degree of renal protection has not been demonstrated for other diabetes medications: while GLP-1 receptor agonists (GLP-1RA) protect from cardiovascular events, they have shown modest renal protective effects on albuminuria and on the decline in kidney function.8, 9, 10